Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras

Journal of Pathology

Volumn 225, Issue 4, 2011, Pages 479-489

  Acin, Sergio ^a   Li, Zhongyou ^a   Mejia, Olga ^a   Roop, Dennis R ^b   El Naggar, Adel K ^a   Caulin, Carlos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

gain of function mutations; head and neck cancer; mouse model; mutant p53; ras

Indexed keywords

CYCLIN A; CYCLIN B1; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; DNA DAMAGE; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; MITOSIS; MOUSE; MOUTH TUMOR; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA DAMAGE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; GENES, P53; GENES, RAS; HEAD AND NECK NEOPLASMS; MICE; MITOSIS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 81355148679     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2971     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Seiwert TY, Salama JK, Vokes EE,. The chemoradiation paradigm in head and neck cancer. Nature Clin Pract Oncol 2007; 4: 156-171.
3. Vokes EE, Weichselbaum RR, Lippman SM, et al., Head and neck cancer. N Engl J Med 1993; 328: 184-194.
4. Culliney B, Birhan A, Young AV, et al., Management of locally advanced or unresectable head and neck cancer. Oncology (Williston Park) 2008; 22: 1152-1161.
5. Califano J, van der Riet P, Westra W, et al., Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-2492.
6. Forastiere A, Koch W, Trotti A, et al., Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
7. El-Naggar AK, Lai S, Luna MA, et al., Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 1995; 64: 196-201.
8. Olshan AF, Weissler MC, Pei H, et al., p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev 1997; 6: 499-504.
9. Andrews GA, Xi S, Pomerantz RG, et al., Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 2004; 26: 870-877.
10. Poeta ML, Manola J, Goldwasser MA, et al., TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
11. Donehower LA, Harvey M, Slagle BL, et al., Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
12. Jacks T, Remington L, Williams BO, et al., Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
13. Hainaut P, Soussi T, Shomer B, et al., Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997; 25: 151-157.
14. Dittmer D, Pati S, Zambetti G, et al., Gain of function mutations in p53. Nature Genet 1993; 4: 42-46.
15. Sun Y, Nakamura K, Wendel E, et al., Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 1993; 90: 2827-2831.
16. Brosh R, Rotter V,. When mutants gain new powers: news from the mutant p53 field. Nature Rev Cancer 2009; 9: 701-713.
17. Perrone F, Bossi P, Cortelazzi B, et al., TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010; 28: 761-766.
18. Shin DM, Lee JS, Lippman SM, et al., p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 519-529.
19. Hassan NM, Tada M, Hamada J, et al., Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. Cancer Lett 2008; 270: 108-119.
20. Lang GA, Iwakuma T, Suh YA, et al., Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
21. Olive KP, Tuveson DA, Ruhe ZC, et al., Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
22. Caulin C, Nguyen T, Lang GA, et al., An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 2007; 117: 1893-1901.
23. Morton JP, Timpson P, Karim SA, et al., Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010; 107: 246-251.
24. Gaiddon C, Lokshin M, Ahn J, et al., A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 1874-1887.
25. Di Agostino S, Strano S, Emiliozzi V, et al., Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
26. Song H, Hollstein M, Xu Y,. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biol 2007; 9: 573-580.
27. Muller PA, Caswell PT, Doyle B, et al., Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
28. Goh AM, Coffill CR, Lane DP,. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126.
29. Oren M, Rotter V,. Mutant p53 gain-of-function in cancer. Cold Spring Harb Protoc 2010; 2: a001107.
30. Caulin C, Nguyen T, Longley MA, et al., Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res 2004; 64: 5054-5058.
31. Jonkers J, Meuwissen R, van der Gulden H, et al., Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet 2001; 29: 418-425.
32. Jackson EL, Willis N, Mercer K, et al., Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
33. Li C, Hung WW,. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001; 2:RESEARCH0032.
34. Dennis G Jr, Sherman BT, Hosack DA, et al., DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4: 3.
35. Roop DR, Cheng CK, Titterington L, et al., Synthetic peptides corresponding to keratin subunits elicit highly specific antibodies. J Biol Chem 1984; 259: 8037-8040.
36. Li B, Murphy KL, Laucirica R, et al., A transgenic mouse model for mammary carcinogenesis. Oncogene 1998; 16: 997-1007.
37. Barrett KL, Demiranda D, Katula KS,. Cyclin B1 promoter activity and functional cdk1 complex formation in G1 phase of human breast cancer cells. Cell Biol Int 2002; 26: 19-28.
38. Hendzel MJ, Wei Y, Mancini MA, et al., Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106: 348-360.
39. Di MR, Fumagalli M, Cicalese A, et al., Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638-642.
40. Bartkova J, Rezaei N, Liontos M, et al., Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
41. Kushner J, Bradley G, Young B, et al., Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J Oral Pathol Med 1999; 28: 77-81.
42. Hassan KA, el Naggar AK, Soria JC, et al., Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin Cancer Res 2001; 7: 2458-2462.
43. Raimondi AR, Molinolo A, Gutkind JS,. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 2009; 69: 4159-4166.
44. Nakayama T, Kaneko M, Kodama M, et al., Cigarette smoke induces DNA single-strand breaks in human cells. Nature 1985; 314: 462-464.
45. Brooks PJ, Theruvathu JA,. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol 2005; 35: 187-193.
46. Liu G, Parant JM, Lang G, et al., Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genet 2004; 36: 63-68.
47. Olivier M, Hollstein M, Hainaut P,. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.